NYSE: FNAParagon 28 Inc Stock
$10.35+0.00 (+0%)
Updated Jan 10, 2025
FNA Price
$10.35
Fair Value Price
N/A
Market Cap
$866.51M
52 Week Low
$4.65
52 Week High
$14.79
P/E
-11.76x
P/B
6.21x
P/S
2.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$245.00M
Earnings
-$72.77M
Gross Margin
71.8%
Operating Margin
-25.08%
Profit Margin
-29.7%
Debt to Equity
1.17
Operating Cash Flow
-$40M
Beta
1.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FNA Overview
Paragon 28, Inc. develops and sells foot and ankle surgical systems in the U.S. and internationally. Offerings include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures. Paragon 28 was founded in 2010 and is headquartered in Englewood, CO.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
C
Sentiment
B
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important FNA news, forecast changes, insider trades & much more!
FNA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FNA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FNA is poor value based on its book value relative to its share price (6.21x), compared to the US Medical Devices industry average (4.01x)
P/B vs Industry Valuation
FNA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FNA due diligence checks available for Premium users.
Valuation
FNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.76x
Industry
37.15x
Market
30.06x
FNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.21x
Industry
4.01x
FNA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FNA's financial health
Profit margin
Revenue
$62.3M
Net Income
-$12.3M
Profit Margin
-19.8%
FNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FNA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$302.0M
Liabilities
$162.6M
Debt to equity
1.17
FNA's short-term assets ($177.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FNA's short-term assets ($177.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$3.8M
Financing
$151.0k
FNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FNA vs Medical Device Stocks
Paragon 28 Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.